access

News

Lilly launches single-dose Zepbound to ease self-pay access

Eli Lilly has launched new single-dose 2.5mg and 5.0mg vials of its obesity drug Zepbound in a move that it said would make it easier for people paying for the drug out-of-pocket to afford

Sales & Marketing

You’re trusted less than a waiter and more than a pilot, but...

Sobering results from a YouGov poll across the UK show that 33–54-year-olds have the least amount of trust in pharmaceutical companies - but the industry is well-placed to regain it.

News

NICE backs osteoporosis drug, but diagnosis is an obstacle

Around 14,000 women in England may soon be able to access a new treatment for osteoporosis after NICE backed routine NHS use of Theramex's Eladynos.

News

BioMarin keeps but scales down Roctavian gene therapy ops

BioMarin Pharma has decided not to divest its haemophilia A gene therapy Roctavian, which has struggled to build much traction in the market, but is reining back its ambitions for the busin

Oncology

Chimeric antigen receptor T-cells: Emerging uses and future ...

Genetic engineering technologies allow for the creation of custom-made cells that can have transformative effects on human health.

R&D

Global medicines and the future outlook

In a conversation held earlier in the year as the four-year anniversary of the pandemic approached, the pharmaphorum podcast had as guest Murray Aitken, executive director of the

Lilly launches single-dose Zepbound to ease self-pay access

You’re trusted less than a waiter and more than a pilot, but...

NICE backs osteoporosis drug, but diagnosis is an obstacle

BioMarin keeps but scales down Roctavian gene therapy ops

Chimeric antigen receptor T-cells: Emerging uses and future ...

Global medicines and the future outlook

Novo sues Lilly over 'misleading' GLP-1 ad campaigning

Discover a new era of healthcare panel engagement: Grounded ...

access

Editor's Picks